Sign In
Buy CABA
$3.58
-0.100 (-2.72%)
At Close: Jun 03, 2026
83% of dermatomyositis patients in the Phase 1/2 RESET-Myositis study would have met the registrational primary endpoint; all these patients maintained their response off immunomodulators through late
Is Cabaletta Bio (CABA) Stock Outpacing Its Medical Peers This Year?
10:40am, Wednesday, 20'th May 2026
Here is how Cabaletta Bio, Inc. (CABA) and Curaleaf Holdings, Inc. (CURLF) have performed compared to their sector so far this year.
Cabaletta Bio (CABA) Upgraded to Buy: Here's Why
01:01pm, Monday, 18'th May 2026
Cabaletta Bio (CABA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Cabaletta Bio Q1 Earnings: More Positive Data Suggests CAR-T Can Work In Autoimmune
10:46am, Thursday, 14'th May 2026
Cabaletta Bio, Inc. is reaffirmed as a Buy despite recent share price volatility, driven by tangible clinical and manufacturing progress. Key catalysts include registrational trials for rese-cel in my
Cabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business Update
07:05am, Thursday, 14'th May 2026
Preconditioning-free (PC-free) 6-to-9-month clinical data with a single infusion of the lowest dose of rese-cel in the RESET-PV ® study presented today at ASGCT 2026 Annual Meeting along with initial
A single infusion of the lowest dose of rese-cel administered without preconditioning, after discontinuation of all immunomodulators, demonstrated compelling drug-free responses for 6 months in 2 of 4
Cabaletta Bio Announces Pricing of $150 Million Underwritten Offering
06:35am, Monday, 04'th May 2026
PHILADELPHIA, May 04, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching cur
Cellares and Cabaletta Bio Sign 10-Year Commercial Supply Agreement to Scale Rese-cel
08:00am, Tuesday, 28'th Apr 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced it has entered into a 10-year commercial supply agreemen
Cabaletta Bio and Cellares Announce 10-Year Commercial Supply Agreement for Rese-cel
08:00am, Tuesday, 28'th Apr 2026
Agreement facilitates flexible, scalable automated industrialized production of rese-cel for many thousands of patients per year at a cost per batch that is among the lowest in the industry Initial
PHILADELPHIA, April 27, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching targeted cell therapies designed sp
First Patients Dosed with Cabaletta Bio's Rese-cel Manufactured on Cellares' Automated Cell Shuttle™ Platform
04:30pm, Tuesday, 14'th Apr 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced that Cabaletta Bio Inc.'s (“Cabaletta Bio” or “Cab
Cabaletta Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
07:30am, Monday, 23'rd Mar 2026
Rese-cel myositis BLA submission on track for 2027 based on a 17-patient, single arm registrational cohort design, including an outpatient dosing option
Cabaletta Bio Highlights Pivotal Myositis Trial, No-Preconditioning CAR-T Push at TD Cowen Conference
01:02am, Monday, 09'th Mar 2026
Cabaletta Bio (NASDAQ: CABA) used a fireside chat at TD Cowen's 46th Annual Health Care Conference to highlight progress across its autoimmune cell therapy program, with executives emphasizing upcomin
Cabaletta Bio (CABA) Upgraded to Buy: Here's What You Should Know
01:01pm, Friday, 06'th Mar 2026
Cabaletta Bio (CABA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Cabaletta Bio to Participate in the TD Cowen 46th Annual Health Care Conference
08:00am, Tuesday, 24'th Feb 2026
PHILADELPHIA, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching the first curative targeted cell the
